Despite centuries since the discovery and study of cancer, cancer is still a lethal and
intractable health issue worldwide. Cancer-associated fibroblasts (CAFs) have gained much …

Chimeric antigen receptor (CAR) T cells have been approved for use in patients with B cell
malignancies or relapsed and/or refractory multiple myeloma, yet efficacy against most solid …

The desmoplastic stroma in solid tumors presents a formidable challenge to
immunotherapies that rely on endogenous or adoptively transferred T cells, however, the …

Cancer immunotherapy has opened a new landscape in cancer treatment, however, the
poor specificity and resistance of most targeted therapeutics have limited their therapeutic …

Pancreatic ductal adenocarcinoma (PDAC) is one of the most lethal solid tumors. The tumor
immune microenvironment (TIME) formed by interactions among cancer cells, immune cells …

Although major progress has been made in the use of chimeric antigen receptor (CAR)-T-
cell therapy for hematological malignancies, this method is ineffective against solid tumors …

Fibroblast activation protein (FAP) is closely related to central nervous system diseases such
as stroke and brain tumors, but PET tracers that can be used for brain imaging have not …

Purpose: Targeting solid tumors with chimeric antigen receptor (CAR) T cells remains
challenging due to heterogenous target antigen expression, antigen escape, and the …

Simple Summary Glioblastoma is the most prevalent cerebral cancer in adults without
proven therapy. Chimeric antigen receptor T cell treatment has demonstrated good clinical …

Fibroblast activation protein (FAP) is tumor-specific and plays an important role in
tumorigenecity. However, agents against its enzymatic activity or extracellular presence …